Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation

Clinical trial NCT03728335 · RECRUITING

Trial details

NCT number: NCT03728335
Sponsor: City of Hope Medical Center
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia

Start date: 2019-07-11
Primary completion: 2027-01-11
Enrollment: 35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.